The results of this single arm trial, which followed 51 patients for a period of up to 14 years, was conducted by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and appeared April 11, 2013, in The New England Journal of Medicine.
Primary mediastinal B-cell lymphoma mainly affects people from their teenage years to their early 30s. Many patients are cured with a combination of chemotherapy and radiation therapy. However, even with this treatment, about 20 percent of patients see their disease progress.
Most patients receive radiation to the chest area, which can cause new cancers as well as damage to the heart. This is particularly a problem for young people because the risk of new cancers and heart disease continues to increase as they get older. Primary mediastinal B-cell lymphoma is also more common in women, who are at greater risk of developing breast cancer from radiation therapy to the chest.
Wyndham Wilson, M.D., Ph.D., head of NCI’s Lymphoma Therapeutics Section, and colleagues conducted the trial, in which every patient received the drugs etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab in a regimen known as dose-adjusted EPOCH-R, or DA-EPOCH-R. This regimen uses infusion strategies in which doses of the drugs etoposide, doxorubicin, and cyclophosphamide are adjusted for greatest efficacy.
Fifty-one patients with untreated primary mediastinal B-cell lymphoma were included in this phase II study. The maximum tumor diameter was 11 centimeters. All but two patients achieved a complete remission with DA-EPOCH-R therapy, and none of the patients with a complete remission have developed a recurrent lymphoma. The two patients who did not achieve a complete remission received radiation and have also not had their tumors recur. There was no evidence of other diseases developing later on or cardiac toxic effects.
“The high success of this regimen in greatly reducing the need for radiation and improving the cure rate in this disease may relate to specialized dosing and continuous infusion delivery of the EPOCH-R agents,” said Wilson.
To provide an independent assessment of their DA-EPOCH-R trial results, the researchers collaborated with investigators at Stanford University (Calif.) Medical Center, who had used this regimen to treat 16 patients with primary mediastinal B-cell lymphoma. The patients were similar to those treated in the NCI study except for being slightly older and having a lower frequency of disease outside the mediastinum. All 16 Stanford patients who received this regimen are also in remission and none required radiation treatment.
Studies have suggested that primary mediastinal B-cell lymphoma has a better outcome with more dose-intense regimens. Other studies have also demonstrated that the use of rituximab in the drug regimen may improve treatment, hence the use of DA-EPOCH-R as opposed to just EPOCH.
“For me, these results are exciting and demonstrate that, using this approach, almost all patients appear to be cured and very few patients require radiation,” said Kieron Dunleavy, M.D., NCI, and first author on the study. “Based on our results, an international phase II trial of DA-EPOCH-R in pediatric patients with primary mediastinal B-cell lymphoma is ongoing to confirm these findings, and we hope this international trial will have a similarly positive outcome.”
The National Cancer Institute (NCI) leads the National Cancer Program and the NIH effort to dramatically reduce the burden of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at http://www.cancer.gov or call NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
NIH…Turning Discovery Into Health ®
Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH. Dose-Adjusted-EPOCH-R Therapy in Primary Mediastinal B-cell Lymphoma. NEJM. April 11, 2013.
NCI Office of Media Relations